Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Head and Neck Surgery

Cutaneous Melanoma: A 2023 Update and Management Pearls

Tuesday, October 3, 2023
8:45 AM - 9:35 AM East Coast USA Time
Location: Ballroom A1

    Lead Presenter(s)

  • Cecelia E. Schmalbach, MD, MSc, FACS

    The David Myers, MD Professor and Chair, Department of Otolaryngology – Head & Neck Surgery
    Temple University
    Philadelphia, PA, United States

    • Co-Presenter(s)

  • Carol R. Bradford, MD

    Dean and Professor of Otolaryngology-Head and Neck Surgery
    The Ohio State University College of Medicine
    Columbus, OH, United States

Disclosure(s):
Cecelia E. Schmalbach, MD, MSc, FACS: No relevant relationships to disclose.
PROGRAM DESCRIPTION: The management of cutaneous head and neck melanoma experienced transformational change over the past several years. This Expert Series provides a contemporary, case-based, concise framework to highlight these changes. The work-up and treatment options for our melanoma patients will be reviewed in an evidence-based fashion. Sentinel node biopsy techniques and pearls will be shared along with the utility of a completion neck dissection in the context of the MSLT-II trial. New advances in targeted therapy to include PD-1 inhibitors and associated clinical trials will be reviewed so that physicians can hold meaningful patient conversations regarding adjuvant treatment options. We will highlight the important changes and associated challenges we face in managing our complex melanoma patients. Participants will leave this 1-hour course with a clear understanding of 2023 standard of care for cutaneous head and neck melanoma.

OUTCOME OBJECTIVE 1: List 2023 evidence-based melanoma guidelines for work-up & staging to include radiographic imaging and sentinel node biopsy

OUTCOME OBJECTIVE 2: Define the utility of a completion neck dissection in the setting of a positive sentinel node given recent MSLT-II trial results

OUTCOME OBJECTIVE 3: Formulate a plan to educate patients on melanoma adjuvant therapy to include novel targeted treatment options

BACKGROUND STATEMENT: A concise melanoma review is of benefit to our AAO-HNS members given the recent introduction of novel targeted therapies (PD-1 inhibitors) & the long awaited MSLT-II results which now question the role of completion neck dissection following a positive sentinel node biopsy.